Filing Flows › Elanco Animal Health (ELAN) › Guidance & outlook
Elanco Animal Health (ELAN) guidance and outlook
Elanco Animal Health (ELAN) raised its guidance on Nov 6, 2026: Revenue $5.2B for FY2026; Revenue +8% for FY2026; EBITDA $1.1B for FY2026; EPS $1.17–$1.20 for FY2026. Elanco Animal Health's 10-Q filed Nov 6, 2026 makes 18 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.3B | raised |
| Revenue | FY2026 | $5.2B | raised |
| Revenue | FY2026 | +8% | raised |
| EBITDA | FY2026 | $1.1B | raised |
| EPS | FY2026 | $1.17–$1.20 | raised |
| Revenue | FY2027 | +5% | new |
| Revenue | Q3 2027 | +4% | new |
| Gross margin | FY2026 | 55.8%–56% | raised |
From the earnings release filed Nov 6, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 6, 2026
- A key element of our targeted value creation strategy is to drive revenue growth through portfolio development and product innovation.
- Zenrelia : We received final FDA approval for Zenrelia ® , a JAK inhibitor targeting control of pruritus and atopic dermatitis in dogs, in September 2024.
- Befrena : In December 2025, we received final approval from the USDA for Befrena ® , a new anti-IL31 monoclonal antibody injection targeting canine allergic and atopic dermatitis.
- Specifically, the 2025 Restructuring Plan targeted an expected 2026 closure of the animal studies portion of our R&D facilities in Monheim, Germany, while also expanding our R&D organization in Indianapolis, Indiana, among other changes to our R&D organization.
- The 2025 Restructuring Plan is also expected to result in our exit from certain farm animal implant products and the related closure of our manufacturing facility in Kansas City, Kansas, in 2026.
- Expected pre-tax charges associated with the 2025 Restructuring Plan total $25 million to $30 million in 2026, of which $18 million was incurred during the nine months ended September 30, 2026, primarily related to the remaining shut-down costs for our Monheim, Germany, facility.
- While the ultimate financial impact of these and other decisions cannot be reasonably estimated at this time, we will continue to closely monitor the trade policies in countries in which we operate and/or from which we import products and continue to take actions, where possible, to mitigate the impacts on our business.
- While the timing and extent of any recoveries remain uncertain, we do not believe the impact of these potential refunds will be material to our business or financial statements.
- The acquisition of AHV is expected to accelerate our strategy to grow our industry
- We expect AHV to contribute modestly to revenue in 2026, with a more meaningful impact beginning in 2027 as we integrate the business and realize commercial synergies.
- This acquisition is not expected to materially affect our deleveraging timeline or overall liquidity position.
- Amounts recorded to asset impairment, restructuring and other special charges during the three and nine months ended September 30, 2025, included asset impairments of $24 million, primarily comprised of $16 million related to two early-stage capital projects that we indefinitely suspended during the third quarter of 2025.
Elanco Animal Health's latest quarter
Elanco Animal Health, Q3 2026: revenue $1.3B (+11% year over year), operating margin 1.9%, net earnings $18.0M, operating cash flow $216M. The chart follows the revenue to costs, profit and cash.
Questions
Did Elanco Animal Health raise or lower its guidance?
Elanco Animal Health (ELAN) raised its guidance on Nov 6, 2026: Revenue $5.2B for FY2026; Revenue +8% for FY2026; EBITDA $1.1B for FY2026; EPS $1.17–$1.20 for FY2026.
What does Elanco Animal Health expect?
A key element of our targeted value creation strategy is to drive revenue growth through portfolio development and product innovation. Zenrelia : We received final FDA approval for Zenrelia ® , a JAK inhibitor targeting control of pruritus and atopic dermatitis in dogs, in September 2024. Befrena : In December 2025, we received final approval from the USDA for Befrena ® , a new anti-IL31 monoclonal antibody injection targeting canine allergic and atopic dermatitis.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.